The MammaSeq assay comprises 79 genes and 1,369 mutations in breast cancer that could be used as potential downstream therapeutic targets.
With the three-year grants, the institutions will continue an initiative that is developing tools and technologies for genome biology research.
The test is designed to analyze a panel of 112 genes to help in the diagnosis of thyroid nodules with indeterminate fine-needle aspiration cytology.
The groups will conduct a study evaluating the benefits of targeted next-generation sequencing in the diagnosis and care of infants with genetic disorders.
National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.
Scientific American reports that drugs being pursued to treat small fraction of Parkinson's disease patients with a certain gene mutation could also help a larger portion of patients.
The genome center will be equipped with five Illumina NovaSeq instruments and will support clinical research at the Immune Therapy and Transplantation Center.
Researchers associated with the Cancer Genome Atlas (TCGA) Research Network will publish more than 25 papers this week to discuss findings from the initiative.
The test was developed by the University of Pittsburgh Medical Center and is marketed in partnership with Sonic Healthcare.
University of Pittsburgh-led team finds that gene therapy could treat mice with type 1 diabetes for a few months, the Los Angeles Times reports.
NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.
Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.
A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.
In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.